Investor Relations

Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies

Read Press Release

Annual Meeting of Shareholders

View All Events

Latest Financial Results

Q1 2020

Quarterly Results

Ended Mar 31, 2020

Stock Information

Symbol NYSE American: OGEN
Price Loading...
Change Loading...
Day Range Loading...
52 Wk Range Loading...

Company Overview

Oragenics is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. In addition, Oragenics, Inc. has established an exclusive worldwide channel collaboration with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria.

Contact Information

Investor Relations
CORE IR
John Marco
Managing Director
T: 310-819-2948
johnm@coreir.com

Transfer Agent
Continental Stock Transfer and Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000